ThailandTuberculosis profile
Population  2014 68 million
Estimates of TB burden * 2014 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 7.4 (3.9–12) 11 (5.7–18)
Mortality (HIV+TB only) 4.5 (2.3–7.4) 6.6 (3.4–11)
Prevalence  (includes HIV+TB) 160 (110–220) 236 (161–326)
Incidence  (includes HIV+TB) 120 (61–190) 171 (90–276)
Incidence (HIV+TB only) 15 (7.8–24) 22 (12–36)
         
Case detection, all forms (%) 59 (36–110)    
Estimates of MDR-TB burden * 2014   New   Retreatment
% of TB cases with MDR-TB 2 (1.4–2.8) 19 (14–25)
MDR-TB cases among notified pulmonary
TB cases
1 100 (780–1 600) 1 100 (800–1 500)
TB case notifications 2014 New ** Relapse
Pulmonary, bacteriologically confirmed 34 394   1 969
Pulmonary, clinically diagnosed 21 115   0
Extrapulmonary 10 244   0
       
Total new and relapse 67 722    
Previously treated, excluding relapses 3 896    
Total cases notified 71 618    
Among 34 394 new cases:
119 (<1%) cases aged under 15 years; male:female ratio: 2.5
Reported cases of RR-/MDR-TB 2014 New Retreatment Total **
Cases tested for RR-/MDR-TB 4 370 (13%) 2 209 (38%) 9 580
Laboratory-confirmed RR-/MDR-TB cases     506
Patients started on MDR-TB treatment ***      
TB/HIV 2014 Number (%)
TB patients with known HIV status 50 670 (71)
HIV-positive TB patients 6 831 (13)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 4 359 (64)
HIV-positive TB patients on antiretroviral therapy (ART) 4 691 (69)
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Treatment success rate and cohort size (%) Cohort
New and relapse cases registered in 2013 (81) 65 867
Previously treated cases, excluding relapse, registered in 2013 (66) 1 812
HIV-positive TB cases, all types, registered in 2013 (67) 7 665
RR-/MDR-TB cases started on second-line treatment in 2012    
XDR-TB cases started on second-line treatment in 2012    
Laboratories 2014  
Smear (per 100 000 population) 1.3
Culture (per 5 million population) 3.9
Drug susceptibility testing (per 5 million population) 1.5
Sites performing Xpert MTB/RIF 14
Is second-line drug susceptibility testing available? Yes, in country
Financing TB control 2015  
National TB programme budget (US$ millions) 32
% Funded domestically 52%
% Funded internationally 11%
% Unfunded 37%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having
RR-/MDR-TB
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-09-27 Data: www.who.int/tb/data